See more : Cardinal Energy Ltd. (CJ.TO) Income Statement Analysis – Financial Results
Complete financial analysis of BioPlus Acquisition Corp. (BIOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioPlus Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Achari Ventures Holdings Corp. I (AVHIW) Income Statement Analysis – Financial Results
- W-SCOPE Corporation (6619.T) Income Statement Analysis – Financial Results
- Syrah Resources Limited (SRHYY) Income Statement Analysis – Financial Results
- Parker Corporation (PRKCF) Income Statement Analysis – Financial Results
- Oriental Shiraishi Corporation (1786.T) Income Statement Analysis – Financial Results
BioPlus Acquisition Corp. (BIOS)
About BioPlus Acquisition Corp.
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
| Metric | 2022 | 2021 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 708.90M | 817.20M | 935.60M | 982.20M | 984.10M | 842.20M | 662.60M | 0.00 | 1.64B | 1.33B | 1.40B | 1.20B | 1.15B | 1.07B | 630.50M | 588.80M | 576.60M | 456.60M | 369.80M | 377.40M | 451.10M | 242.30M | 283.20M | 213.90M | 109.30M | 100.00K |
| Cost of Revenue | 1.17M | 0.00 | 465.90M | 547.90M | 670.00M | 721.30M | 723.00M | 570.40M | 437.70M | 0.00 | 1.38B | 1.17B | 1.26B | 1.06B | 1.03B | 957.00M | 562.40M | 520.20M | 506.00M | 403.20M | 334.60M | 347.10M | 421.40M | 239.00M | 278.10M | 213.40M | 106.70M | 0.00 |
| Gross Profit | -1.17M | 0.00 | 243.00M | 269.30M | 265.60M | 260.90M | 261.10M | 271.80M | 224.90M | 0.00 | 260.40M | 157.80M | 142.20M | 137.00M | 119.60M | 116.20M | 68.10M | 68.60M | 70.60M | 53.40M | 35.20M | 30.30M | 29.70M | 3.30M | 5.10M | 500.00K | 2.60M | 100.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 34.28% | 32.95% | 28.39% | 26.56% | 26.53% | 32.27% | 33.94% | 0.00% | 15.89% | 11.87% | 10.14% | 11.44% | 10.38% | 10.83% | 10.80% | 11.65% | 12.24% | 11.70% | 9.52% | 8.03% | 6.58% | 1.36% | 1.80% | 0.23% | 2.38% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 47.30M | 63.30M | 66.00M | 83.60M | 319.40M | 254.00M | 198.50M | 0.00 | 226.30M | 140.60M | 129.10M | 125.30M | 129.20M | 109.30M | 52.80M | 50.60M | 45.90M | 38.50M | 33.90M | 28.00M | 23.10M | 19.10M | 11.60M | 8.00M | 5.30M | 100.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.17K | 162.43 | 47.30M | 63.30M | 66.00M | 83.60M | 319.40M | 254.00M | 198.50M | 0.00 | 226.30M | 140.60M | 129.10M | 125.30M | 129.20M | 109.30M | 52.80M | 50.60M | 45.90M | 38.50M | 33.90M | 28.00M | 23.10M | 19.10M | 11.60M | 8.00M | 5.30M | 100.00K |
| Other Expenses | 1.17M | 0.00 | 189.60M | 220.80M | 197.70M | 465.00M | 35.10M | 40.70M | 13.10M | 4.80M | 27.90M | 1.80M | 96.60M | 2.90M | 6.60M | 36.10M | 3.00M | 1.90M | 500.00K | -200.00K | 1.50M | 7.10M | 4.00M | 0.00 | 26.60M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.17M | 162.43 | 236.90M | 284.10M | 263.70M | 548.60M | 354.50M | 294.70M | 211.60M | 4.80M | 254.20M | 142.40M | 225.70M | 128.20M | 135.80M | 145.40M | 55.80M | 52.50M | 46.40M | 38.30M | 35.40M | 35.10M | 27.10M | 19.10M | 38.20M | 8.00M | 5.30M | 100.00K |
| Cost & Expenses | 1.17M | 162.43 | 702.80M | 832.00M | 933.70M | 1.27B | 1.08B | 865.10M | 649.30M | 4.80M | 1.63B | 1.31B | 1.49B | 1.19B | 1.17B | 1.10B | 618.20M | 572.70M | 552.40M | 441.50M | 370.00M | 382.20M | 448.50M | 258.10M | 316.30M | 221.40M | 112.00M | 100.00K |
| Interest Income | 3.17M | 9.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | -57.40M | -52.10M | -38.20M | -37.30M | -38.50M | 28.20M | 26.07M | 28.31M | -27.60M | -1.90M | -2.70M | -3.30M | -3.00M | -400.00K | -800.00K | -800.00K | -800.00K | -100.00K | 800.00K | 1.00M | 1.70M | 2.30M | 1.40M | 700.00K | 200.00K | 0.00 |
| Depreciation & Amortization | 228.49K | 236.56K | 23.60M | 27.73M | 21.55M | 22.74M | -81.10M | -16.10M | 73.07M | 15.88M | 12.33M | 5.03M | 6.40M | 7.09M | 10.86M | 9.92M | 5.03M | 5.08M | 6.06M | 6.36M | 4.88M | 3.22M | 1.69M | 1.09M | 780.00K | 370.00K | 90.00K | 0.00 |
| EBITDA | -1.17M | 9.49 | -84.90M | -24.97M | -56.15M | -335.76M | -174.60M | -39.00M | 86.37M | 39.39M | -36.67M | 16.63M | -82.50M | 9.39M | -11.44M | -19.98M | 15.73M | 19.48M | 28.66M | 21.36M | 3.98M | 420.00K | 7.69M | -10.11M | -29.62M | -5.73M | -2.21M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | -11.98% | -3.06% | -6.00% | -34.18% | -17.74% | -4.63% | 13.03% | 0.00% | -2.24% | 1.25% | -5.88% | 0.78% | -0.99% | -1.86% | 2.49% | 3.31% | 4.97% | 4.68% | 1.08% | 0.11% | 1.70% | -4.17% | -10.46% | -2.68% | -2.02% | 0.00% |
| Operating Income | -1.17M | -162.43 | -108.50M | -52.70M | -77.70M | -358.50M | -93.50M | -22.90M | 13.30M | 23.51M | -49.00M | 11.60M | -88.90M | 2.30M | -22.30M | -29.90M | 10.70M | 14.40M | 22.60M | 15.00M | -900.00K | -2.80M | 6.00M | -11.20M | -30.40M | -6.10M | -2.30M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -15.31% | -6.45% | -8.30% | -36.50% | -9.50% | -2.72% | 2.01% | 0.00% | -2.99% | 0.87% | -6.34% | 0.19% | -1.93% | -2.79% | 1.70% | 2.45% | 3.92% | 3.29% | -0.24% | -0.74% | 1.33% | -4.62% | -10.73% | -2.85% | -2.10% | 0.00% |
| Total Other Income/Expenses | 3.17M | 9.49 | 57.50M | -14.70M | 45.30M | 33.50M | -38.50M | -28.20M | -26.10M | -28.31M | 27.60M | 1.90M | 2.70M | 3.30M | 3.00M | 300.00K | 800.00K | 800.00K | 800.00K | 100.00K | -800.00K | -1.00M | -1.70M | -2.30M | -1.40M | -700.00K | -200.00K | 0.00 |
| Income Before Tax | 2.00M | -152.95 | -51.00M | -67.40M | -32.40M | -325.00M | -132.00M | -51.10M | -12.80M | -4.80M | -21.40M | 13.50M | -86.20M | 5.60M | -19.30M | -29.60M | 11.50M | 15.20M | 23.40M | 15.10M | -1.70M | -3.80M | 4.30M | -13.50M | -31.80M | -6.80M | -2.50M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -7.19% | -8.25% | -3.46% | -33.09% | -13.41% | -6.07% | -1.93% | 0.00% | -1.31% | 1.02% | -6.15% | 0.47% | -1.67% | -2.76% | 1.82% | 2.58% | 4.06% | 3.31% | -0.46% | -1.01% | 0.95% | -5.57% | -11.23% | -3.18% | -2.29% | 0.00% |
| Income Tax Expense | -3.17M | 9.49 | 600.00K | 63.60M | 2.00M | -21.50M | 11.40M | 2.50M | -4.40M | 28.31M | 47.70M | -40.60M | -12.20M | 2.30M | 19.00M | -5.70M | 4.50M | 6.10M | 4.70M | 900.00K | 100.00K | 1.00M | 1.70M | 2.30M | 1.40M | 700.00K | 200.00K | 0.00 |
| Net Income | 5.16M | -152.95 | -51.60M | -131.00M | -34.40M | -303.50M | -143.40M | -53.60M | -8.40M | -33.11M | -69.10M | 54.10M | -74.00M | 3.30M | -38.30M | -23.90M | 7.00M | 9.10M | 18.70M | 14.20M | -1.80M | -4.80M | 2.60M | -15.80M | -33.20M | -7.50M | -2.70M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | -7.28% | -16.03% | -3.68% | -30.90% | -14.57% | -6.36% | -1.27% | 0.00% | -4.22% | 4.07% | -5.28% | 0.28% | -3.32% | -2.23% | 1.11% | 1.55% | 3.24% | 3.11% | -0.49% | -1.27% | 0.58% | -6.52% | -11.72% | -3.51% | -2.47% | 0.00% |
| EPS | 0.01 | -0.02 | -0.40 | -1.06 | -0.37 | -4.42 | -2.09 | -0.83 | -0.15 | -0.60 | -1.37 | 1.36 | -1.93 | 0.09 | -1.03 | -0.70 | 0.31 | 0.40 | 0.79 | 0.64 | -0.09 | -0.26 | 0.16 | -1.25 | -3.46 | -1.60 | -0.60 | 0.00 |
| EPS Diluted | 0.01 | -0.02 | -0.40 | -1.06 | -0.37 | -4.42 | -2.09 | -0.83 | -0.15 | -0.60 | -1.37 | 1.36 | -1.93 | 0.09 | -1.03 | -0.70 | 0.31 | 0.40 | 0.79 | 0.64 | -0.09 | -0.26 | 0.16 | -1.25 | -3.46 | -1.60 | -0.60 | 0.00 |
| Weighted Avg Shares Out | 597.79M | 6.88K | 127.90M | 123.80M | 93.70M | 68.70M | 68.50M | 64.60M | 56.20M | 55.20M | 50.40M | 39.70M | 38.40M | 38.50M | 37.30M | 34.10M | 22.70M | 22.60M | 23.60M | 22.30M | 19.90M | 18.70M | 16.30M | 12.60M | 9.60M | 4.70M | 4.50M | 4.50M |
| Weighted Avg Shares Out (Dil) | 597.79M | 6.88K | 127.90M | 123.80M | 93.70M | 68.70M | 68.50M | 64.60M | 56.20M | 55.20M | 50.40M | 39.70M | 38.40M | 38.50M | 37.30M | 34.10M | 22.70M | 22.60M | 23.60M | 22.30M | 19.90M | 18.70M | 16.30M | 12.60M | 9.60M | 4.70M | 4.50M | 4.50M |
BioScrip Sells Assets of Specialty Pharmacies and Centralized Specialty and Mail Service Pharmacy to Walgreens
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ: BIOS) (the “Company”) today announced that it has signed a definitive agreement to sell certain assets of its community specialty pharmacies and centralized specialty and mail service pharmacy businesses (the “Transferred Businesses”) to Walgreens Co....
BioScrip to Present at BOCEMb Noble Financial Capital Markets Eighth Annual Equity Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at the BOCEMb Noble Financial Capital Markets Eighth Annual Equity Conference to be held Tuesday, January 17 and Wednesday, January 18, 2012 at the Hard Rock Hotel in...
BioScrip to Present at 30th Annual J.P. Morgan Healthcare Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at the 30th Annual J.P. Morgan Healthcare Conference to be held Monday, January 9 - Thursday, January 12, 2012 at the Westin St. Francis Hotel in San Francisco....
BioScrip to Present at Oppenheimer 22nd Annual Healthcare Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at the Oppenheimer 22nd Annual Healthcare Conference to be held Tuesday, December 13 - Wednesday, December 14, 2011 at The Waldorf Astoria in New York City, NY. Richard...
BioScrip to Present at Bank of America Merrill Lynch Leveraged Finance Conference
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at the Bank of America Merrill Lynch Leveraged Finance Conference to be held Wednesday, November 30 - Friday, December 2, 2011 at the Loews Royal Pacific Resort at...
BioScrip Reports 2011 Third Quarter Financial Results
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (Nasdaq: BIOS) today announced 2011 third quarter financial results. Revenue for the three months ended September 30, 2011 was $454.0 million and net income was $0.5 million, or $0.01 per diluted share, including $5.0 million in...
BioScrip to Host Third Quarter 2011 Earnings Call
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will release its 2011 third quarter financial results before the market opens on Tuesday, November 8, 2011, and host a conference call at 8:30 a.m. Eastern Standard Time (EST) to...
BioScrip to Present at Upcoming Investor Conferences
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will present at two investor conferences in September. Monday, September 19, 2011 at 12:00 pm EDT - At the UBS Global Life Sciences Conference, to be held September 19-21, 2011,...
BioScrip Reports 2011 Second Quarter Financial Results
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (Nasdaq: BIOS) today announced 2011 second quarter financial results. Second quarter revenue for the period ended June 30, 2011, was $441.4 million with a net loss of $2.3 million, or $0.04 per share, including $8.7 million...
BioScrip to Host Second Quarter 2011 Earnings Call
ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip (NASDAQ: BIOS) today announced that the Company will release its 2011 second quarter financial results before the market open on Monday, August 8, 2011, and host a conference call at 8:30 a.m. Eastern Time (ET) to discuss...
Source: https://incomestatements.info
Category: Stock Reports